111 related articles for article (PubMed ID: 7471314)
1. Clinical pharmacology of tamoxifen and N-desmethyltamoxifen in patients with advanced breast cancer.
Wilkinson P; Ribeiro G; Adam H; Patterson J
Cancer Chemother Pharmacol; 1980; 5(2):109-11. PubMed ID: 7471314
[TBL] [Abstract][Full Text] [Related]
2. Implications of tamoxifen metabolism in the athymic mouse for the study of antitumor effects upon human breast cancer xenografts.
Robinson SP; Langan-Fahey SM; Jordan VC
Eur J Cancer Clin Oncol; 1989 Dec; 25(12):1769-76. PubMed ID: 2632258
[TBL] [Abstract][Full Text] [Related]
3. Effect of oestrogen receptor status and time on the intra-tumoural accumulation of tamoxifen and N-desmethyltamoxifen following short-term therapy in human primary breast cancer.
Johnston SR; Haynes BP; Sacks NP; McKinna JA; Griggs LJ; Jarman M; Baum M; Smith IE; Dowsett M
Breast Cancer Res Treat; 1993 Dec; 28(3):241-50. PubMed ID: 8018953
[TBL] [Abstract][Full Text] [Related]
4. Comparative binding affinities of tamoxifen, 4-hydroxytamoxifen, and desmethyltamoxifen for estrogen receptors isolated from human breast carcinoma: correlation with blood levels in patients with metastatic breast cancer.
Fabian C; Tilzer L; Sternson L
Biopharm Drug Dispos; 1981; 2(4):381-90. PubMed ID: 7317574
[TBL] [Abstract][Full Text] [Related]
5. The steady-state pharmacokinetics of tamoxifen and its metabolites in breast cancer patients.
Soininen K; Kleimola T; Elomaa I; Salmo M; Rissanen P
J Int Med Res; 1986; 14(3):162-5. PubMed ID: 3522312
[TBL] [Abstract][Full Text] [Related]
6. Determination and pharmacology of a new hydroxylated metabolite of tamoxifen observed in patient sera during therapy for advanced breast cancer.
Jordan VC; Bain RR; Brown RR; Gosden B; Santos MA
Cancer Res; 1983 Mar; 43(3):1446-50. PubMed ID: 6825112
[TBL] [Abstract][Full Text] [Related]
7. Tamoxifen and metabolite concentrations in serum and breast cancer tissue during three dose regimens in a randomized preoperative trial.
Kisanga ER; Gjerde J; Guerrieri-Gonzaga A; Pigatto F; Pesci-Feltri A; Robertson C; Serrano D; Pelosi G; Decensi A; Lien EA
Clin Cancer Res; 2004 Apr; 10(7):2336-43. PubMed ID: 15073109
[TBL] [Abstract][Full Text] [Related]
8. Tamoxifen metabolites in patients on long-term adjuvant therapy for breast cancer.
Langan-Fahey SM; Tormey DC; Jordan VC
Eur J Cancer; 1990; 26(8):883-8. PubMed ID: 2145931
[TBL] [Abstract][Full Text] [Related]
9. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen.
Lim YC; Desta Z; Flockhart DA; Skaar TC
Cancer Chemother Pharmacol; 2005 May; 55(5):471-8. PubMed ID: 15685451
[TBL] [Abstract][Full Text] [Related]
10. Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats and mice compared to the breast cancer patient.
Robinson SP; Langan-Fahey SM; Johnson DA; Jordan VC
Drug Metab Dispos; 1991; 19(1):36-43. PubMed ID: 1673419
[TBL] [Abstract][Full Text] [Related]
11. Distribution of 4-hydroxy-N-desmethyltamoxifen and other tamoxifen metabolites in human biological fluids during tamoxifen treatment.
Lien EA; Solheim E; Lea OA; Lundgren S; Kvinnsland S; Ueland PM
Cancer Res; 1989 Apr; 49(8):2175-83. PubMed ID: 2702659
[TBL] [Abstract][Full Text] [Related]
12. Distribution of tamoxifen and metabolites into brain tissue and brain metastases in breast cancer patients.
Lien EA; Wester K; Lønning PE; Solheim E; Ueland PM
Br J Cancer; 1991 Apr; 63(4):641-5. PubMed ID: 2021551
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen dose and serum concentrations of tamoxifen and six of its metabolites in routine clinical outpatient care.
Jager NG; Rosing H; Schellens JH; Linn SC; Beijnen JH
Breast Cancer Res Treat; 2014 Feb; 143(3):477-83. PubMed ID: 24390246
[TBL] [Abstract][Full Text] [Related]
14. Aging may be associated with concentrations of tamoxifen and its metabolites in breast cancer patients.
Sheth HR; Lord G; Tkaczuk K; Danton M; Lewis LM; Langenberg P; Lim CK; Flaws JA
J Womens Health (Larchmt); 2003 Oct; 12(8):799-808. PubMed ID: 14588130
[TBL] [Abstract][Full Text] [Related]
15. Vaginal tamoxifen for treatment of vulvar and vaginal atrophy: Pharmacokinetics and local tolerance in a rabbit model over 28 days.
Chollet J; Mermelstein F; Rocamboli SC; Friend DR
Int J Pharm; 2019 Oct; 570():118691. PubMed ID: 31518632
[TBL] [Abstract][Full Text] [Related]
16. Association of tamoxifen (TAM) and TAM metabolite concentrations with self-reported side effects of TAM in women with breast cancer.
Gallicchio L; Lord G; Tkaczuk K; Danton M; Lewis LM; Lim CK; Flaws JA
Breast Cancer Res Treat; 2004 May; 85(1):89-97. PubMed ID: 15039600
[TBL] [Abstract][Full Text] [Related]
17. Identification of tamoxifen metabolites in human Hep G2 cell line, human liver homogenate, and patients on long-term therapy for breast cancer.
Poon GK; Walter B; Lønning PE; Horton MN; McCague R
Drug Metab Dispos; 1995 Mar; 23(3):377-82. PubMed ID: 7628304
[TBL] [Abstract][Full Text] [Related]
18. Tissue distribution of 4-hydroxy-N-desmethyltamoxifen and tamoxifen-N-oxide.
Gjerde J; Gandini S; Guerrieri-Gonzaga A; Haugan Moi LL; Aristarco V; Mellgren G; Decensi A; Lien EA
Breast Cancer Res Treat; 2012 Jul; 134(2):693-700. PubMed ID: 22562123
[TBL] [Abstract][Full Text] [Related]
19. Pronounced Interindividual But Not Intraindividual Variation in Tamoxifen and Metabolite Levels in Plasma During Adjuvant Treatment of Women With Early Breast Cancer.
Fotoohi AK; Karim H; Lafolie P; Pohanka A; Östervall J; Hatschek T; Vitols S
Ther Drug Monit; 2016 Apr; 38(2):239-45. PubMed ID: 26485084
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial.
Dowsett M; Cuzick J; Howell A; Jackson I;
Br J Cancer; 2001 Aug; 85(3):317-24. PubMed ID: 11487258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]